World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
110
Citations
42633
World Ranking
895
National Ranking
545

Medicine

D-Index
111
Citations
43579
World Ranking
5349
National Ranking
2888

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award

Overview

Deborah A. Thomas is a researcher affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their work spans multiple disciplines primarily within Medicine and Social Sciences, with a notable focus on areas such as Genetics, Sociology and Political Science, Epidemiology, Surgery, and Public Health, Environmental and Occupational Health.

Their research topics encompass a range of subjects including Inflammatory Bowel Disease, Microscopic Colitis, Caribbean history, culture, and politics, Cuban History and Society, Helicobacter pylori-related gastroenterology studies, Menstrual Health and Disorders, and Health and Wellbeing Research.

Key recent publications by Deborah A. Thomas include:

  • Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease, 2022, Crohn's & Colitis 360
  • A Multimodal Qualitative Approach to Understanding Menstrual Health Equity among Adolescents and Young Adults, 2023, Journal of Pediatric and Adolescent Gynecology
  • 19th Century United States Newspaper images predicted as Photographs with labels for "human", "animal", "human-structure" and "landscape", 2022, arXiv (Cornell University)
  • Displacements, 2020, Small Axe A Caribbean Journal of Criticism
  • Early Treatment with Ofatumumab in Patients with High-Risk CLL, 2022, Blood

Frequent coauthors collaborating with Deborah A. Thomas include:

  • April J. Mayes
  • Patricia Mohammed
  • Martin Munro
  • Michelle Stephens
  • Yolanda Martínez-San

Their work is often published in venues such as:

  • Crohn's & Colitis 360
  • Journal of Pediatric and Adolescent Gynecology
  • Small Axe A Caribbean Journal of Criticism
  • PEDIATRICS
  • Blood

Best Publications

  • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

    Alan List;Gordon Dewald;John Bennett;Aristotle Giagounidis

  • Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

    Srdan Verstovsek;Hagop Kantarjian;Ruben A. Mesa;Animesh D. Pardanani

  • Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

    Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner

  • Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

    Jean Pierre J. Issa;Guillermo Garcia-Manero;Francis J. Giles;Rajan Mannari

  • Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

    Alvaro Aguayo;Hagop M Kantarjian;Taghi Manshouri;Cristi Gidel

  • Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

    Constantine S. Tam;Susan O'Brien;William Wierda;Hagop Kantarjian

  • Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

    Hagop Kantarjian;Deborah Thomas;Susan O'Brien;Jorge Cortes

  • Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia

    Susan M. O’Brien;Hagop Kantarjian;Deborah A. Thomas;Francis J. Giles

  • Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

    Deborah A. Thomas;Stefan Faderl;Jorge Cortes;Susan O'Brien

  • Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

    William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl

  • Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

    Deborah A. Thomas;Stefan Faderl;Susan O'Brien;Carlos Bueso-Ramos

  • Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

    Azra Raza;James A. Reeves;Eric J. Feldman;Gordon W. Dewald

  • High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia

    Hagop Kantarjian;Moshe Talpaz;Susan O'Brien;Guillermo Garcia-Manero

  • Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

    Deborah A. Thomas;Susan O'Brien;Stefan Faderl;Guillermo Garcia-Manero

  • Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

    Farhad Ravandi;Jorge E Cortes;Daniel Jones;Stefan H Faderl

  • Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

    Hagop M. Kantarjian;Deborah A. Thomas;Jeffrey L. Jorgensen;Elias Joseph Jabbour

  • Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

    William G. Wierda;Susan O'Brien;Xuemei Wang;Stefan Faderl

  • Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.

    Hagop M. Kantarjian;Moshe Talpaz;Susan O'Brien;Francis Giles

  • Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

    Karen W.L. Yee;Zhihong Zeng;Marina Konopleva;Srdan Verstovsek

  • Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

    Ruben A. Mesa;Srdan Verstovsek;Francisco Cervantes;Giovanni Barosi

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Susan O'Brien
Susan O'Brien University of California, Irvine
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Francis J. Giles
Francis J. Giles Northwestern University
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens the door to many rewarding and flexible career paths, especially in the nursing and healthcare professions. Online degree options are making these pathways even more accessible for students balancing work, family, and study.

For current registered nurses aiming to advance their education, rn to bsn online programs offer a flexible route to a bachelor’s degree. Similarly, those interested in educational or leadership positions can consider doctorate in nursing education online programs to further their expertise and open doors to high-level roles.

Prospective students without a nursing background can pursue a nursing career through direct entry msn programs, which provide a streamlined pathway to becoming a registered nurse. Additionally, online bsn programs for non nurses can offer accessible and less competitive entry points into the profession.

Exploring these online options allows students to find degree programs that fit their unique needs and career goals while maintaining the flexibility modern life requires.

Best Scientists Citing Deborah A. Thomas

Trending Scientists